Doxorubicin PopPK Simulator
Indication: Cancer chemotherapy
Interactive population PK simulator for doxorubicin, an anthracycline chemotherapy used in breast cancer, lymphoma, and other malignancies. Models IV pharmacokinetics with exposure context relevant to efficacy and cardiotoxicity risk.
Drug Overview
Clinical Context
- Molecular Target
- Topoisomerase II and DNA via intercalation and free radical-mediated damage
- Drug Class
- Anthracycline
- Therapeutic Area
- Oncology
- Indication
- Cancer chemotherapy
- Route of Administration
- IV
Model Information
- Model Type
- popPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Doxorubicin allows you to explore concentration-time profiles under different dosing scenarios. The underlying popPK model characterizes the pharmacokinetics of this anthracycline following iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Doxorubicin PK simulator?
This is a free, interactive pharmacokinetic simulator for Doxorubicin used in Cancer chemotherapy. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Doxorubicin belong to?
Doxorubicin is classified as a Anthracycline that targets Topoisomerase II and DNA via intercalation and free radical-mediated damage. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV administration of Doxorubicin. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a popPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses
Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens
Docetaxel
Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer
Capecitabine and 5-FU
Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma
PBPK-PD of ADCs
Exposure and ILD risk assessment for trastuzumab deruxtecan and related ADC therapy
Ready to Simulate?
Launch the Doxorubicin simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community